Mark Meininghaus is a Senior Research Scientist at Bayer Pharmaceuticals, specializing in cell-based assay development with a particular focus on miniaturized iPSC-derived cardiomyocyte setups. With over 20 years of experience in ultra-high throughput screening on cutting-edge robotic platforms, they have contributed to various roles within Bayer since 2007. Mark also held a position as a Senior Research Associate at the Broad Institute of MIT and Harvard in 2016.
Location
Wuppertal, Germany
This person is not in any teams